Review Article
Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
Table 1
Comparison of efficacy results from the PACCE and CAIRO2 studies.
| | PACCE oxaliplatin cohort [43] | CAIRO2 [47] | | () | () | | Ox + Bev + Pmab | Ox + Bev | Cap, Ox + Bev + Cmab | Cap, Ox + Bev |
| | Median progression-free survival (95% CI), mo | 10.0 (8.9–11.0) | 11.4 (10.5–11.9) | 9.4 (8.4–10.5) | 10.7 (9.7–12.3) | | Progression-free survival events, (%) | 246 (60) | 221 (54) | 316 (84) | 293 (78) | | Overall response rate, %* | 46 | 48 | 50.0 | 52.7 | | Median overall survival (95% CI), mo | 19.4 (18.4–20.8) | 24.5 (20.4–24.5) | 20.3 (17.8–24.7) | 19.4 (17.5–21.4) | | Deaths, (%) | 143 (35) | 108 (26) | 214 (57) | 193 (51) |
|
|
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation; Pmab: panitumumab.
*Overall response rate = complete response + partial response.
|
